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Aterosklerosis merupakan salah satu penyebab utama penyakit vaskular di 
seluruh dunia dan menyebabkan progresi penyakit klinis seperti serangan jantung, 
stroke, dan kematian. Lp-PLA2 merupakan enzim yang diproduksi sel-sel inflamasi dan 
bersifat pro aterogenik pada proses aterosklerosis. Dalam prosesnya, monosit akan 
menginduksi penghasilan Lp-PLA2. Lp-PLA2 akan menghidrolisi oxLDL dan 
menghasilkan lysophosphatidylcholine (lysoPC) dan oxidized fatty acids (oxFA) yang 
memperberatkan aterosklerosis. Penelitian ini bertujuan untuk mengetahui korelasi 
konsentrasi Lp-PLA2 dengan monosit pada populasi dengan kondisi risiko 
aterosklerosis. Penelitian ini deskriptif analitik korelasional pada populasi dengan 
kondisi risiko aterosklerosis. Sampling dilakukan dengan metode total sampling 
dengan responden sejumlah 86 orang. Lp-PLA2 diukur menggunakan metode ELISA 
sedangkan monosit diukur menggunkan Hematology Analyzer. Hasil penelitian 
menunjukkan bahwa terdapat korelasi yang signifikan antara Lp-PLA2 dengan monosit 
(p=0,028;a<0,050) dan koefisien korelasinya adalah 0,789. Kesimpulan dari penelitian 
ini adalah peningkatan konsentrasi Lp-PLA2 berkorelasi dengan peningkatan monosit 
pada populasi dengan resiko aterosklerosis. 
 
 


































Vijayadas, Dinesh. 2018. Analysis Of Correlation Between Concentration Of 
Lp-PLA2 (Lipoprotein-Associated Phospolipase A2) And The 
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           Atherosclerosis is one of the main causes of vascular disease throughout the 
world and cause clinical disease progressions such as heart attack, stroke, and lead to 
death. Lp-PLA2 is an enzyme produced by inflammatory cells and pro atherogenic in 
the process of atherosclerosis. In the process, monocytes will produce Lp-PLA2. Lp-
PLA2 will hydrolyze oxLDL into lysophosphatidylcholine (lysoPC) and oxidized fatty 
acids (oxFA) which are atherogenic. Aim of the research is to determine the correlation 
of Lp-PLA2 concentration with number and percentages in populations with conditions 
at risk of atherosclerosis. This study was descriptive correlational analytic on the 
population with conditions at risk of atherosclerosis. Sampling was done by the total 
sampling method with 86 respondents. ELISA method used to measure Lp-PLA2 
concentration and the Hematology Analyzer method used to measure number and 
percentage of monocyte. The results showed that at the Lp-PLA2 concentration has a 
significant correlation with number and percentage of monocyte (p = 0.028;a <0.050) 
with correlation coefficient 0.789 which shows the relationship is strong. The conclusion 
of this research is that an increase in the concentration of Lp-PLA2 correlates with an 
increase in number and percentage of monocyte on population with conditions at risk 
of atherosclerosis. 
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SHORT FORM LISTS 
ACC-AHA :  American College Of Cardiology and the American Heart Association 
ACS         :  Acute Coronary Syndrome 
ASCVD    :  Atherosclerotic Cardiovascular Disease 
BMI          :  Body Mass Index 
BPJS        :  Badan Penyelengaraan Jaminan Sosial 
CCR2       :  Chemokine Receptor Type 2 
CD115+   :  Cluster Of Differentiation 115+ 
CHD        :  Coronary Heart Disease 
CVD        :   Cardiovascular Disease 
DM          :  Diabetes Mellitus 
EC          :  Endothelial Cell 
HDL.        :  High Density Lipoprotein 
ICAM-1    :  Intercellular adhesion molecule 1 
IL-1b        :  Interleukin 1 Beta 
LDL          :  Low Density Lipoprotein 
Lp-PLA2   :  Lipoprotein-Associated Phospholipase A2 
Ly-6c       :  Lymphocyte antigen 6 complex 
Lyso-PC.  :  lysophosphatidylcholine 
oxFA.       :  oxidized fatty acids 
oxLDL.    :  Oxidised Low Density Lipoprotein 
PAI-1       :  Plasminogen Activator Inhibitor 1 
SCORE   :  Systemic Coronary Risk Evaluation 
TG           :  Triglyceride 
TNF-a    : Tumor Necrosis Factor Alpha 
VCAM-1 :  Vascular cell adhesion molecule 1 

























Cardiovascular Disease (CVD) is the largest cause of death worldwide. 
According to WHO, the main cause of people’s death in the world is cardiovascular 
disease. More than 17.9 million people died from CVD in 2017 with the percentage of 
31% of all deaths in the world, of which 85% of them were die due to heart disease 
such as heart attack and stroke. (WHO, 2017).  
In Indonesia, coronary heart disease cause atherosclerosis quite common. 
According to Riskesdas year 2013, the prevalence of the occurrence of coronary heart 
disease is as much as 1.5% of the entire population. Financing of catastrophic 
diseases, according to social security governing body data (BPJS) health year 2015, 
cost nearly 14.3 Trillion Rupiah and in the year 2016 cost nearly 14.6 Trillion Rupiah. 
The biggest expense is spent for heart disease, which gained from the year 2015, i.e. 
of 6.9 trillion rupiahs (48.25%) being to 7.4 trillion rupiahs (50.7%) in 2016 (Kemenkes 
RI, 2017). While in East Java, the prevalence of coronary heart disease is 1.3% or 
about 582,000 cases (Riskesdas 2013). 
Atherosclerosis is one of the most threatening disease in most developing 
countries as well as developed countries. High mortality rate has been registered due 
to this disease. There are many risk factors such as smoking, dyslipidimia and 
hypertension that lead to atherosclerosis. It actually begins with dysfunction of 
endothelial. Endothelial plays the main role in vasomotor abnormalities and  
inflammatory response (Coleman, 2010). Endothelial dysfunction happens due to 
inflammatory response followed by plaque formation. Plaque is made from cholesterol, 
fatty acid, calcium and fibrin. This will lead to blockage at the artery wall. This will reduce 






















There are many risk factors inducing the progression of atherosclerosis.The risk 
factors are divide into two groups which known as modifiable and non-modifiable risk 
factors. The non-modifiable risk factors are genetic, gender and age. The modifiable 
risk factor are obesity, smoking habits, diabetes mellitus, systolic blood pressure and 
dyslipidemia. Dyslipidemia plays major role in initiation of atherosclerosis especially in 
the conditions of hyperlipidemia. 
Hyperlipidemia such as triglycerides, cholesterol, and lipoproteins plays major 
role in the formation of atherogenesis. Decreased HDL lipoprotein concentrations and 
elevated triglycerides including LDL have been shown to be responsible for the genesis 
of atherosclerotic lesions (Hilgendorf, 2015). This leads to the constriction to the 
coronary artery lumen. This resulting in decreased blood flow and oxygen supply 
disruption to the myocardium. In the course of the illness, CHD can be progressive and 
there is often a sudden change from a stable state to an acute state known as acute 
coronary syndrome (ACS). The abrupt change mechanism is associated with the 
occurrence of acute thrombosis in atherosclerotic plaque that is eroded, cracked or 
ruptured. The rupture of atherosclerotic plaque is associated with stable atherosclerotic 
plaque changes that are volatile and easily torn. Laboratory tests are now also intended 
to detect early plaque phase changes prior to arterial plaque rupture (Jaipersad, 2014). 
Arterial plaque rupture will cause lesion. This lesion will leads circulating 
monocytes to the lesion area. The interaction between leukocyte, platelets, and blood 
vessel cells lead to the production of monocyte in bone marrow and release it into an 
artery and attach to the endothelial cell. Continuous recruitment of monocyte to the 
lesion will cause the accumulation of macrophages. Macrophage will ingest oxidized 
lipoprotein into developing plaques through scavenger receptors. (Stone, 2014). 
In this process monocyte, lymphocytes and mast cell produce Lipoprotein-
associated phospholipase A2 (LP-PLA2). LP-PLA2  will hydrolyze oxLDL and produce 






















will cause endothelial dysfunction, inducing apoptosis of smooth muscle cells and 
macrophages that cause the expansion of the necrotic nucleus of atherosclerotic 
plaque, fibrous capsule depletion, and destabilization of plaque resulting in rupture of 
arterial plaque. This will be the initial stage of atherosclerosis (Colley, 2011). 
Few new researches also done to investigate the role of LP-PLA2  in the 
formation of atherosclerosis such as Nisha Dada and his teammate done a research 
on LP-PLA2 an emerging biomarker or coronary heart disease (Nisha Dada,2014). This 
shows that lipoprotein-associated phospholipase A2 (LP-PLA2) is a novel candidate for 
plaque destabilization and a marker of endothelial dysfunction, which is the initial phase 
of atherosclerosis and plays a role in risk stratification in ACS. The increase in LP-PLA2  
in blood able to indicate the atherogenesis (Colley, 2011).  
Monocyte/macrophage produce LP-PLA2  in the presence of the modifiable and 
non-modifiable risk factors that lead to the pathogenesis of atherosclerosis. LP-PLA2  
breakdown oxLDL into two component which are lysoPC and OxFA. Both of the 
component induce formation of fibrous cap soon will lead to CVD. This proved both 
these components playing role in the process of atherogenesis. Further research need 
to be done to find their correlation and significant role in the pathogenesis of 
atherosclerosis (Sarihati, 2017). 
 
1.2 Problem Statement 
 Is there correlation between concentration of LP-PLA2 with the number and 
percentage of monocyte on the population with conditions at risk of atherosclerosis 
























1.3 Objective Of Research 
 This research has 2 outline purposes, which is a general purpose and a specific 
purpose.  
1.3.1 General Purpose 
 To prove there is a relationship between concentration of LP-PLA2  with the 
number and percentage of monocyte on a population with conditions at risk of 
atherosclerosis 
. 
1.3.2 Specific Purpose 
a. To measure the concentration of LP-PLA2  on the population with conditions at 
risk of atherosclerosis 
b. To measure the number and percentage of monocyte on the population with 
conditions at risk of atherosclerosis 
c. To analyze the correlation between the number and percentage of monocyte 
and concentration of LP-PLA2  on the population with conditions at risk of 
atherosclerosis 
1.4 Significance Of Research 
 This research has two outline significance. 
1.4.1 Scientific Significance 
To develop a new biomarker which are LP-PLA2  and monocyte for the detection 
of the atherogenesis 
1.4.2 Practical Significance 
a. To use LP-PLA2  and monocytes as early detector of the occurance of 
atherosclerosis 


























2.1.1 Definition of Atherosclerosis 
Atherosclerosis is one of the most threatening disease in most developing 
countries as well as developed countries. High mortality rate has been registered due 
to this disease. There are many risk factors such as smoking, dyslipidimia and 
hypertension that lead to atherosclerosis. It actually begins with dysfunction of 
endothelial. Endothelial plays the main role in vasomotor abnormalities and  
inflammatory response (Coleman, 2010). Endothelial dysfunction happens due to 
inflammatory response followed by plaque formation. Plaque is made of cholesterol, 
fatty acid, calcium and fibrin. This will lead to blockage at the artery wall. This will reduce 
the flow of blood and oxygen supply (Libby et al.., 2012).  
Constriction of the coronary artery lumen due to atherosclerosis, resulting in 
decreased blood flow and oxygen supply disruption to the myocardium. In the course 
of the illness, CHD can be progressive and there is often a sudden change from a stable 
state to an acute state known as acute coronary syndrome (ACS). The abrupt change 
mechanism is associated with the occurrence of acute thrombosis in atherosclerotic 
plaque that is eroded, cracked or ruptured. The rupture of atherosclerotic plaque is 
associated with stable atherosclerotic plaque changes that are volatile and easily torn. 
Laboratory tests are now also intended to detect early plaque phase changes prior to 
arterial plaque rupture (Jaipersad, 2014). 
Arterial plaque rupture will cause lesion. This lesion will leads circulating 
monocytes to the lesion area. The interaction between leukocyte, platelets, and blood 
vessel cells lead to the production of monocyte in bone marrow and release it into an 






















lesion will cause the accumulation of macrophages. Macrophage will ingest oxidized 
lipoprotein into developing plaques through scavenger receptors (Stone, 2014). 
In this process macrophages cause the expansion of the necrotic nucleus of 
atherosclerotic plaque, fibrous capsule depletion, and destabilization of plaque 
resulting in rupture of arterial plaque. This will be the initiation of atherosclerosis (Colley, 
2011). 
 
2.1.2 Epidemiology, Incidence, dan Prevalence 
Cardiovascular Disease (CVD) is the largest cause of death worldwide. 
According to WHO, the main cause of people’s death in the world is cardiovascular 
disease. More than 17.9 million people died from CVD in 2017 with the percentage of 
31% of all deaths in the world, of which 85% of them were die due to heart disease 
such as heart attack and stroke (WHO, 2017). 
Most Asian countries experience challenges from cardiovascular disease, with 
mortality rates varying from 103 to 366 per 100000 adults reported by newly published 
studies. Increased cholesterol levels in the population become a frequent cause. 
Elderly men and people with dyslipidemia, hypertension, and diabetes are individuals 
at high risk of cardiovascular disease. Over the past decade, there has been a tendency 
of increased escalating atherosclerotic charges, especially in East Asia, where a 
surprising increase of 117.2% and 115.3% of total deaths and disability-adjusted for 
years was observed (An, 2015). 
In Indonesia, coronary heart disease cause atherosclerosis quite common. 
According to Riskesdas year 2013, the prevalence of the occurrence of coronary heart 
disease is as much as 1.5% of the entire population. Financing of catastrophic 
diseases, according to social security governing body data (BPJS) health year 2015, 
cost nearly 14.3 Trillion Rupiah and in the year 2016 cost nearly 14.6 Trillion Rupiah. 






















of 6.9 trillion rupiahs (48.25%) being to 7.4 trillion rupiahs (50.7%) in 2016 (Kemenkes 
RI, 2017). While in East Java, the prevalence of coronary heart disease is 1.3% or 
about 582,000 cases (Riskesdas 2013). 
 
2.1.3 Risk Factor Of Atherosclerosis 
Atherosclerosis can be developed with a variety of different risk factors among 
individuals one and other. Based on etiology, the risk factors for atherosclerosis is 
divided into two major groups, risk factors that can be modified and the risk factors that 
cannot be modified. 
 
2.1.3.1 Modifiable Risk Factors 
a. Obesity 
Individuals whose BMI range in between 25 to 29.9 kg/m2 are classified as 
overweight also known as obesity (M. Piche, 2018). The research done by Francisco 
et al proved that overweight and obesity associated with cardiovascular disease. High 
level fat mass contributed cardiovascular risk factor such as plasma lipids, insulin 
resistance, blood pressure and inflammation. It shows that in obese patient more blood 
circulate which increase cardiac output and increase the burden of heart to pump it all 
over the body. Later on it will end up in heart failure (Francisco B, 2016).   
Fat levels in the blood is a significant factor in the occurrence of atherosclerosis. 
Some of the important components in fat are LDL, HDL, and triglycerides (TG) which 
increased risk of occurrence atherosclerosis. A decrease in cholesterol levels 1 mmol/L 
in the blood can lower atherosclerosis risks as much as 17% (Lewington et al., 2007). 
Gain of excessive body weight also known as obesity will increase the amount of 
























b. Smoking Habits 
Cigarette smoking known as one of modifiable risk factor for cardiovascular 
disease. This is because the contents of the cigarette which toxify human body. The 
level of toxicity is depend on the smoking behavior of the individual and the amount of 
cigarette smoked. According to WHO, smoking is responsible for 10% of cardiovascular 
cases (Barbara Messner, 2014). 
The US General Surgeon report of 1964 suggests that smoking is a definite risk 
factor for changes in inflammatory and thrombotic biomarkers. This evidence suggests 
a clear link between smoking and the mechanism of atherosclerotic disease and 
increases the risk of CHD by twice (Kwon, 2016). 
Oxidant substance, Carbon monoxide and nicotine in the cigarette play role in 
the pathophysiology of cardiovascular disease resulting from smoking. These 
substance lead to atherothrombosis and changes in the vascular endothelium (Murat 
Akcay, 2017). 
c. Diabetes Mellitus 
Type 2 diabetes mellitus has long been considered a disease associated with 
increased risk of cardiovascular disease morbidity and mortality. In addition, many 
studies have found biological mechanisms associated with DM that independently 
increase the risk of CVD in diabetic patients. Therefore, targeting Cardiovascular risk 
factors in patients with DM is critical to minimize the long-term cardiovascular 
complications of the disease (J. Steinberger, 2003). 
Hyperinsulinemia can induce the formation of foam cell that can contribute to 
the occurrence of atherosclerosis in patients with type 2 diabetes mellitus (Park et al., 
2012). In addition, blood coagulability increased in DM2 due to increased plasminogen 
activator inhibitor 1 (PAI-1) and increased platelet aggregation capability. In addition, 






















fibrinogen, haptoglobin, α-macroglobulin as well as clotting factors that increase the 
risk of thrombosis due to increased blood viscosity (Parrinello, 2015). 
            d.Systolic Blood Pressure 
            Hypertension is the leading global preventable risk factor for cardiovascular 
disease (CVD) and premature Observational epidemiologic studies have shown a 
strong, independent, and log-linear association between usual systolic blood pressure 
(SBP) and mortality from CVD (J. Bundy, 2017). 
           People with high systolic blood pressure related to cardiovascular disease 
expecially atherosclerosis. This happen due to high blood pressure against the blood 
vessel cause damage at the blood vessel. This will lead to the formation of lesion where 
indirectly cause narrowing of blood vessel and build up of plaque. The narrow blood 
vessel will cause the supply of oxygen to body reduce and increase the cardiac output 
to compensate the oxygen level (James Beckerman, 2018). 
e. Lipid Profile (Dyslipidemia) 
The members of the Expert Panel acknowledge the important contributions 
arising from decades of genetic and biochemical studies, observational epidemiological 
and ecological studies, and in vitro and animal experiments that associated higher low-
density lipoprotein cholesterol (LDL-C) levels with greater ASCVD risk. These studies 
provided the rationale for RCTs, which in turn demonstrated that lowering cholesterol 
levels reduced ASCVD events (N. Stone, 2014). 
Decreased HDL lipoprotein concentrations and elevated triglycerides including 
LDL have been shown to be responsible for the genesis of atherosclerotic lesions. LDL 
retention in the walls of blood vessels experienced oxidation to oxLDL promotes 
recruitment and retention of monocytes that would later become macrophages. This 























2.1.3.2 Unmodifiable Risk Factors 
a. Genetic 
Genetic-epidemiological studies have identified a list of astonishing genetic and 
non-genetic factors for cardiovascular disease. However, such studies show that family 
history is the most significant independent risk factor. Many of Mendel's disorders 
associated with atherosclerosis, such as familial hypercholesterolemia (FH), have been 
characterized, but they only explain a small percentage of susceptibility to disease 
although most early cardiovascular disease. Most cases of myocardial infarction (MI) 
and stroke are caused by the interaction of several genetic factors and the environment, 
which nothing can cause disease by itself (Khera, 2016). 
b. Gender 
Cardiovascular disease is the leading cause of death and morbidity in women 
after the age of 50 in most developed countries. Epidemiology, symptoms and 
development of cardiovascular disease are different in women than in men. Indeed, 
women have a higher risk of getting cardiovascular disease when they are about 10 
years older than men and usually after menopause (Hak, 2000). 
              c. Age 
           The older the people the higher the risk of getting atherosclerosis. Genetic or 
lifestyle factors cause plaque to form in the arteries as you get older. By the time you 
are middle-aged or older, Enough plaques are formed to cause signs or symptoms. In 
men, the risk increases after the age of 45 years. In women, the risk increases after the 
age of 55 years (Skali, 2015). 
 
2.1.4 Risk Factor Assessment For Atherosclerosis 
There many ways to measure the risk factors such as ASCVD Risk Algorithm, 























2.1.4.1  ACC-AHA Risk Algorithm 
The American College of Cardiology (ACC) and the American Heart Association 
(AHA) have recently developed a new standard for treating blood cholesterol. The main 
purpose of the new cholesterol practice guidelines is to reduce the risk of heart attack, 
stroke and death of a person. For this reason, the focus is not just measuring and 
treating cholesterol, but also identifying whether someone already has or is at risk of 
developing atherosclerotic cardiovascular disease (ASCVD) based on the modifiable 
and non modifiable risk factors such as age, gender, smoking habits, total cholesterol 
and systolic blood pressure and may benefit from treatment. This practice guide 
outlines the most effective treatment that lowers blood cholesterol in people who are 
most likely to benefit. Most importantly, they are selected as the best strategy for 
lowering cholesterol to help reduce the risk of future heart attacks or strokes (Goff, 
2014). 
 
2.1.4.2 The Systematic Coronary Risk Evaluation (SCORE) 
The Systematic Coronary Risk Evaluation (SCORE) is one of the predictors of 
heart disease risk which was initiated by the European Societies of Cardiology with 
Hypertension and the European Atherosclerosis Society in 1994. Some components 
are made as the reference for SCORE measurement systems such as gender, age, 
the presence of a smoking habit, total cholesterol, and systolic blood pressure. These 
components will then be adjusted to the specified table on the calculation SCORE. 
There are six groups of classifications of risk provided by this system, which will 
interpret the results of this risk of fatal cardiovascular disease in high-risk populations 























2.1.5 Pathogenesis Of Atherosclerosis 
     The word Atherosclerosis is derived from Yunani. Athere means the 
accumulation of lipid and Sclerosis means friction. The overall process of 
atherosclerosis is happened due to aggregation of cholesterol, infiltrate macrophage 
and proliferation of smooth muscle cell at the endothelium of blood vessel. This cause 
the endothelium become weaken and lead to rupture of blood vessel wall. Circulating 
activated platelets and platelet-leukocyte/monocyte aggregates promote the formation 
of atherosclerotic lesions (Yu, 2013). 
The risk factors such as hyperlipidemia, smoking habits, hypertension, genetic 
factors, living lifestyle, systolic blood pressure and diabetes mellitus enhance the 
pathogenesis of atherosclerosis through damage the endothelium of the wall of blood 
vessel. Hyperlipidemia which means in this situation is triglyceride, cholesterol, and 
lipoprotein. The reduction of HDL and the increase in LDL lead to the accumulation of 
fatty acid at the endothelium. The precipitation of LDL at the blood vessel will be 
oxidized and form oxLDL (Chasman, 2009) 
OxLDL is formed and retained in the sub-endothelial space, activating 
endothelial cells (ECs) through the induction of cell surface adhesion molecules which, 
in turn, induces the rolling and adhesion of blood monocytes and T cells. It is reported 
that OxLDL induces the expression of intercellular adhesion molecule (ICAM-1) and 
vascular cell-1 adhesion molecule (VCAM-1), Enhancing the endothelial adhesive 
properties in a manner similar to the pro-inflammatory effects. Cytokine as interleukin 
1 beta. The recruited blood monocyte migrate to the intimal tunica, guided by 
chemokine. Indeed, OxLDL stimulates the endothelial cells and smooth muscle cells 
initiate to the recruitment of monocytes to the endothelial wall. On the other hand, 























Macrophages in atherosclerotic lesions produce foam cells that contain lipid 
droplets. The accumulation of foam cells contributes to lipid storage and atherosclerotic 
plaque growth. The atherosclerotic plaque has a decreased ability to migrate, leading 
to the resolution of inflammation and the development of further lesions into complex 
atherosclerotic plaques. At this stage, macrophages contribute to the maintenance of 
local inflammatory responses by secreting proinflammatory cytokines and chemokine 
and producing reactive oxygen species. The atherosclerotic plaque will inhibit 
monocyte reaction and stimulate efflux cholesterol. Thus, if there is generalized 
endothelial cell damage in atherosclerosis, then there must also be a proportional 
increase in improvement if the intimal is to avoid de-endothelialization (Rafieian-Kopaei 
et al., 2014). 
 
Figure 2 : Progression Of Atherosclerotic Plaque (Rafieian-Kopaei et al., 2014) 
The further consequences of vascular atherosclerosis are angiogenesis of vasa 
vasorum in arterial media and adventitia, in response to ischemic following arteriolar 
occlusion. Such consequences can be dangerous because angiogenesis in 
neovascularization of blood vessels affected by atherosclerosis can cause atheroma 

























   There are many endogenous factors affecting the occurrence of 
atherosclerosis, both protective factors or induce factors. Monocyte is one of the 
protective and induce factors that protect and lead towards the occurrence of 
atherosclerosis. 
2.2.1 Roles Of Monocyte 
Monocytes are white blood cells that are related to granulocytes, which are 
white blood cells designed to kill bacteria. Monocytes are produced in bone marrow 
and then released into the bloodstream. Young monocyte cells start as monoblasts in 
the bone marrow. Once released, they leave the bone marrow and circulate through 
the bloodstream for a few hours before finding their way to other tissues, such as the 
spleen and lungs. Once monocytes are embedded in those tissues, they become 
macrophages. Macrophages support healthy immune function by destroying and 
ingesting pathogens. They also help lymphocyte cells recognize pathogens and create 
antibodies against them (Swirski et al., 2009). 
The innate immune system begins to defend against microorganisms quickly 
and efficiently, and monocytes are a major player of innate immunity. Monocytes 
consist of 10% and 4% of human blood leukocytes and mouse. The main part of the 
CD115 + monocyte in mice expresses low levels of Ly-6c, CCR2 and CD62L, and low 
CX3CR11 levels. Ly-6c high monocytes are recruited to inflamed sites and produce 
high-level pro-inflammatory cytokines, such as TNF-α and IL-1β. Therefore, Ly-6c high 
monocytes are called inflammatory monocytes. The second part of the monocyte 
mouse expresses a high level of CX3CR1 and a low Ly-6c level. They are in blood 
vessels in a steady state and may play an important role in scavenging oxidized lipids, 
dead cells, and pathogens. Both monocyte subsets circulate in the blood and survey 
the established tissues by transporting the antigen itself to the lymph node with minimal 






















in inflammatory sites3. At least 3 monocyte subsets exist in humans. CD14 ++ CD16-
monocytes resembling Ly-6c high mouse monocytes, CD14 ++ CD16 + monocytes 
have a proinflammatory role, and CD14 + CD16 ++ monocytes show patrol behaviour 
similar to Ly-6c low mouse monocyte (Hilgendorf, 2015). 
 
2.2.2 The Role Of Monocyte In Development Of Atherosclerosis 
Rupture at the blood vessel will cause lesion. This lesion will attract the 
circulating monocytes to lesion area. The interaction between leukocytes, platelets, and 
blood vessel cells lead to the production of monocyte in bone marrow and release to 
circulating blood. Continuous recruitment of monocyte to the lesion will cause the 
accumulation of macrophages. Macrophages ingest oxidized lipoproteins through 
scavenger receptors and lipid-rich cells, contributing to the physical part of plaque 
development (Stone, 2014).  
In this process macrophages, lymphocytes and mast cell produce Lipoprotein-
associated phospholipase A2 (LP-PLA2).  LP-PLA2  will hydrolyze oxLDL and produce 
lysophosphatidylcholine (lysoPC) and oxidized fatty acids (oxFA). LysoPC and oxFA 
will cause endothelial dysfunction, inducing apoptosis of smooth muscle cells and 
macrophages that cause the expansion of the necrotic nucleus of atherosclerotic 
plaque, fibrous capsule depletion, and destabilization of plaque resulting in rupture of 
arterial plaque. This will be the initial stage of atherosclerosis (Colley, 2011). 
 
2.3 Lipoprotein-Associated Phospholipase A2 (LP-PLA2 ) 
2.3.1 Definition Of LP-PLA2  
     A chronicle inflammatory process occurs at different stages of 
atherosclerosis. LP-PLA2  hydrolysis oxidized LDL short chain (oxLDL) into 






















atherosclerotic plaque and areas rich in macrophages. This shows LP-PLA2  able to be 
a biomarker in seeing the development of atherogenesis (McIntyre et al., 2009). 
LP-PLA2  has lately been using as the therapeutic approach in the field of 
cardiology. Based on the role of pathophysiology owned by LP-PLA2  form the nature 
of pro-inflammatory and pro-atherogenesis, there is a lot of epidemiological data which 
indicates that the increased expression of LP-PLA2  will increase the risk of 
cardiovascular disease. In addition, many clinical studies have indicated that increase 
LP-PLA2  affect the occurrence of Endothelial dysfunction. It thus provides a great 
opportunity in the development of therapeutic targets. This is because the specific 
enzyme inhibitors and treatment data on animals try promising positive initials, as well 
as data from experiments on human beings, has been available (Koenig, 2010). 
2.3.2 Role Of LP-PLA2  On Occurrence Of Atherosclerosis 
Lipoprotein Phospholipase A2 (LP-PLA2), is an enzyme produced by 
inflammatory cells that function to cleave oxidized phospholipids. LP-PLA2  produces 
pro-inflammatory parts of lysophosphatidylcholine and oxidized fatty acids that act as 
monocyte chemoattractants and activate macrophages. The localization of LP-PLA2  in 
atherosclerotic lesions and their association with plaque instability supports a potential 

























Figure 3 : Role Of Lp-PLA2  In The Formation Of Atherosclerotic Plaque 
(D.Steen, M.O’Donoghue, 2013) 
Explanation : LP-PLA2  is highly specific for vascular inflammation, has low biological 
variability, and plays a causative role in atherosclerotic plaque inflammation. It belongs 
to the group of intracellular and secretory phospholipase enzymes that can hydrolyze 
sn-2 phospholipid ester bond of cellular membranes and lipoproteins. LP-PLA2  enzyme 
is formed by macrophages and foam cells in atherosclerotic plaque, and is associated 
primarily with LDL particles in blood. LP-PLA2  that is bound to LDL is the sole enzyme 
responsible for hydrolysis of oxidized phospholipids (oxPL) on LDL particles. LP-PLA2  
hydrolyzes oxPL at the surface of lipoproteins, but has weak activity against non-oxPL. 
LP-PLA2  is also the enzyme that hydrolyzes oxPL on HDL particles, where it may have 
a role in the antioxidative function of HDL. The distribution of LP-PLA2  between LDL 
and HDL particles depends on the extent of LP-PLA2  glycosylation, which may affect 
the activity of LP-PLA2  in plasma. Stable atherosclerotic plaques contain few 
inflammatory cells and a small amount of LP-PLA2 . In contrast, unstable plaques most 
often do not have significant impact on arterial lumen but may be detected by its thin 






















between stable and unstable atherosclerotic plaque may also be the presence of 
activated inflammatory cells and increased LP-PLA2  concentration in unstable plaque. 
These new insights indicate that LP-PLA2 may be a risk factor, which is important for 
the formation of atherosclerotic plaque but also for its rupture (D.Steen, M.O’Donoghue, 
2013) 
LP-PLA2  mass association (circulating antigen level) and activity (circulating 
enzymatic activity) CVD has been examined in several prospective studies. Most but 
not all reported the association LP-PLA2  with the risk of CVD events in the future. One 
study showed that activity may be more associated with CVD risk factors compared 
with the mass. This study is primarily conducted in middle-aged adults where vulnerable 
and ruptured plaques are usually associated with sudden cardiac death. LP-PLA2  is 
reported to be expressed in this type of lesion. There is limited data on the relationship 
between LP-PLA2  and CVD in older adults who have stable plaques. Because plaque 
morphology can change with age, the association of LP-PLA2  with CVD may differ with 



































CONCEPTUAL FRAMEWORK AND HYPOTHESIS 






























Induce :  
1.ICAM-1 
2.VCAM-1 
3.Interleukin 1 Beta 
pathogenesis of
atherosclerosis
Figure 3.1 Conceptual Framework 






















3.2 Conceptual Framework Description 
 
          Atherosclerosis can be developed with a variety of different risk factors among 
individuals one and other. Based on etiology, the risk factors for atherosclerosis is 
divided into two major groups. Risk factors that can be modified such as smoking 
habits, total cholesterol, HDL and systolic blood pressure. Risk factors that cannot be 
modified such as age and gender. Atherosclerosis is happened due to aggregation of 
cholesterol, infiltrate macrophage and proliferation of smooth muscle cell at the 
endothelium of blood vessel. LP-PLA2  is a modified form of LDL that could interfere 
with fibrinolysis by competing with plasminogen for binding to cells. LP-PLA2  also binds 
to macrophages to promote foam cell formation and deposition of cholesterol in 
atherosclerotic plaques. Thus, Lp-LPA2 accelerates atherosclerosis process by 
impairing fibrinolysis and increasing LDL oxidation (Wayne W. LaMorte, MD, PhD, 
2016). 
         OxLDL is formed and retained in the sub-endothelial space, activating endothelial 
cells through the induction of cell surface adhesion molecules which, in turn, induces 
the rolling and adhesion of blood monocytes and T cells. It is reported that OxLDL 
induces the expression of intercellular adhesion molecule (ICAM-1) and vascular cell-
1 adhesion molecule (VCAM-1), Enhancing the endothelial adhesive properties in a 
manner similar to the pro-inflammatory effects. Cytokine as interleukin 1 beta. The 
recruited blood monocyte migrate to the intimal tunica, guided by chemokine. Indeed, 
OxLDL stimulates the endothelial cells and smooth muscle cells initiate to the 
recruitment of monocytes to the endothelial wall. OxLDL will also react with enzyme Lp 
- PLA2 and broken down OxLDL into Lyso - PC and oxidized fatty acid. Adhesion of 
the molecule is initiated. Foam cell will undergo apoptosis. Thrombocytes will activate 
and aggregrate and lead to fibrous cap formation. This lead to progression of 
atherosclerosis (Cai ET AL., 2013). 
 
3.3 Research Hypothesis 
 Correlation between LP-PLA2  and monocyte on the population with risk of 
atherosclerosis  is directly proportional and correlated to one and other which means 


























4.1 Research Design 
 This research was a survey with Case Control Study on Population with High 
Risk of getting Atherosclerosis. The research was an observational analytic research 
using cross sectional study approach. The research was done by using  human venous 
blood sampling to determine the concentration of LP-PLA2  and monocyte. The 
significance of concentration of LP-PLA2  is used as a predictor of atherosclerosis 
events. Then the difference of LP-PLA2  expression pattern in both groups observed. 
The research was conducted after obtaining approval from the Medical Research 
Ethics Committee of UB's Medical Faculty : No.277 / EC / KEPK - S1 - PD / 11 / 2018. 
 
4.2 Population  
               People who attended the health examination with risk factors of 
atherosclerosis based on ACC - AHA in some areas in Malang city. 
4.2.1 Sample Population 
The sample population of this research was chosen by total sampling among 
86 people who attended the health examination with risk factors of atherosclerosis 
based on ACC - AHA in some areas in Malang city. 
 
4.3 Place And  Time Of Research 
              This research began with blood sampling and filling survey form in the city of 
Malang. Full blood examination was done in the laboratory of the Central Regional 
Hospital Saiful Anwar Malang. The measurement of the concentration of LP-PLA2  and 
monocytes were conducted in the Bioscience Laboratory UB. Results of the study then 






















4.4 Research Variables  
     In a research basically there will be independent variables and dependent variables. 
The independent variable is a stable variable and is not affected by other variables that 
want to be measured. This refers to systematically manipulated experimental 
conditions. While the dependent variable, is a variable that depends on other factors 
being measured. This variable is expected to change as a result of the experimental 
manipulations of the independent variables. 
4.4.1 Independent Variable 
 In this research, concentration of Lp-PLA2 was the independent variable. 
4.4.2 Dependent Variable 
 In this research, number and percentage  was the dependent variable. 
4.5 Operational Definition 
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4.6 Instrument Used For Research (Materials dan Tools) 
4.6.1 The Blood Sampling Tools 
1. Spuit 
2. Wing needle 
3. Alcohol swab 
4. Container EDTA 




4.6.2 ELISA Examination Tools 
1. ELISA kit LP-PLA2  
2. Pipette 
3. Stripplate microelisa 
4. Standard Buffer Sollution 
5. Incubator 
6. HRP-Conjugated Reagent 






















8. Microtiter Plate Reader atau ELISA reader 
 
4.7 Research Procedure 
 Ethical clearance is done at the early stages. Then high risk population of 
atherosclerosis was chosen and blood sample taken from them through the vein 
puncture. The blood sample later send to University Brawijaya Bioscience Lab to 
analysis concentration of LP-PLA2  and rate of monocytes.  
4.7.1 Veinpuncture Prosedure 
1. Asked the patient to straighten her hand then grip the fist. 
2. Installed the tourniquet 5-10cm above the fossa cubiti. 
3. Palpate the fossa cubiti to locate the vein. 
4. The fossa cubiti was clean with alcohol swab.  
5. Pierced the syringe at the marked area till the blood entered the spuit. 
6. When enough blood collected the tourniquet released. 
7. The syringe removed from the fossa cubiti and placed cotton on it. 
8. The blood sample entered into EDTA vacutainer. 
9. Labeled the vacutainer according to the patient’s identity. 
4.7.2 Sample measurement of LP-PLA2  
 The measurement is done by the method of ELISA: 
1. Enter the sample into the EDTA vacutainer contained anticoagulant and 
intubated for 10-20 minutes. 
2. Centrifuged the vacutainer for 20 minutes at 2000-3000 rpm. 
3. Dilute with standard buffer solution contain 50µL with concentration 9 ng/ml, 6 
ng/ml, 3 ng/ml, 1.5 ng/ml, 0.75 ng/ml. 
4. Let the empty tube for controls on stripplate microelisa. On the tube samples, 
enter 40 µ L sample buffer solution and  10 µL sample buffer solution with 






















5. Intubated for 30 minutes under the temperature of 37°C. 
6. Dilute the concentrated buffer with water. 
7. Add 50 µ L HRP-Conjugated reagent to each tube, except for the control tube. 
8. Incubate the solution and washed it back. 
9. Added 50 µL chromogen A dan chromogen B  solution into both tubes and 
shaked well. Intubate atp 37°C for 15 minutes. Avoid direct light. 
10. Add 50 µL stop anti-dilution provisions into each tube to stop the reaction.The 
color on the tube will change from blue to yellow. 
11. Read the optical density at 450 absorption nm using a Microtiter Plate 
Reader.The optical density values on the control set at zero value. 
 
4.7.3 Sample measurement of Monocyte 
The measurement is done by the method of Hematology Analyzer : 
1. Fill a capillary tube ½ to ¾ full with blood. Let the specimen flow down the tube 
until it is near the dry end.  
2. Insert the dry end vertically into the sealant, pushing it to the bottom of the tray. 
3. Twist the tube when removing it from the sealant to prevent the sealing plug 
from being extracted.  
4. Gently tap the sealed end of the tube on a flat surface to help insure proper 
sealant contact in the tube.  
5. Wipe off the prepared capillary tube.  
6. Place the capillary tube carefully in the centrifuge tube holder with the sealant 
end down. Do not force the tube; let it slide into the tube holder.  
7. All tube positions are numbered on the rotor and can be used to record the 
position of each patient specimen. 
8. With the tube holders and hematocrit tubes in place, lock the lid by firmly 






















9. Centrifuge the specimen. 
 
4.8 Data Analysis  
 Data analysis were done one the results of the research using statistical 
analysis SPSS (Statistical Product of Service Solution) version 24 for Windows. The 
data is significant when 0,05% (p<0,05).  
 



















Questionnaire Data Retrieval 
Blood sample collected 
 Enzyme-Linked Immunosorbent 
Assay (ELISA) Procedure 
• Concetration of LP-
PLA2  
























RESEARCH RESULTS AND DATA ANALYSIS 
 
            The aim of this research is to investigate the relationship between LP-PLA2  
and monocytes on the population with risk factors of atherosclerosis . The sample 
measured from low expression till high expression. The research undergo on 86 
people with risk factor of atherosclerosis. Following are the data obtained. This 
research were done after get approval from the Ethic Commission as following : No. 
277 / EC / KEPK – S1 – PD / 11 / 2018. 
 
5.1 Research Results 
5.1.1 Characteristic Of Data 
 The data below shows the characteristic of the 86 peoples based on the age 
category, gender, body mass index (BMI), smoking habits, blood pressure, fasting 


































Table 5.1. Characteristic Of The Respondent Data  
 
Variable Subject 












Male 48 (56%) 0,10580 0,2873 7.26 









30 – 49 24 (28%) 0,10367 0,2819 7.18 
50 – 69 51 (59%) 0,10702 0,2654 6.89 
70 – 89  
 








Smoker 27 (31%) 0,10316 0,2946 7.43 













Underweight 6 (7%) 0,10788 0,2874 7.00 
Normal 
Weight 
34 (40%) 0,10574 0,2694 6.78 
Overweight 20 (23%) 0,10381 0,2741 7.24 
Obese 
Class I 
15 (17%) 0,10781 0,2509 7.16 
Obese 
Class II 

























































<70 mg/dL 45 (52%) 0,10637 0,2686 6.75 
70 – 99 
mg/dL 
17 (20%) 0,10525 0,2646 7.46 













Dyslipidemia 75 (87%) 0,10541 0,2711 7.01 
Non-
dyslipidemia 




86 (100%) 0,072 0,041 
 
 
5.1.1.1 Demographic Analysis Of Respondent Characteristic 
             Based on table 5.1, the homogeneity of the data is different. Those data 
which are homogen, One Way ANOVA were used to find the significance (P value) 
meanwhile non–homogen data used Mann Whitney or Kruskal Wallis to find the 
significance (P value). Based on the P value, the significance (p<0,05) potray by 
gender, age, smoking habits, body mass index(BMI), blood pressure, fasting blood 
sugar and lipid profile for monocyte meanwhile in Lp-PLA2  only gender, age, body 
























5.1.1.1.1 Gender and Age  
Gender are classified into two categary which is male and female. Age is one of 
the contributing risk factor for the occurrence of atherosclerosis. The age were 
categorized start from 30 years old till 89 years old with interval 20 for each age group. 
Based on table 5.1, the majority of the sample population are male which are 
56% meanwhile female are 44%. The table also showing that the majority of population 
in between the age gap 50-69 years old which consist of 59% and the minority of the 
population are the age gap in between 70-89 years old which consist of 13%. 
Based on the table 5.1, the highest mean of LP-PLA2  is own by the male with 
0,10580 ng/mL and the highest mean for number and percentage of monocyte also 
own by the male with 0,2873 103/µL and 7.26%. The highest mean of LP-PLA2  is shown 
at the age group 50-69 years old with 0,10702 ng/mL meanwhile the highest mean for 
number and percentage of monocyte shown at the age group 70-89 years old with 
0,2836 103/µL and 7.14%. The significance show by gender with Lp-PLA2 and 
monocyte are 0,032 and 0,042 and significance show by age with Lp-PLA2 and 
monocyte are 0,025 and 0,034 which means the relationship between age and gender 
with monocyte and Lp-PLA2  are significant. 
5.1.1.1.2 Smoking Habits 
Based on the characteristic data smoking habits able to categorized into two 
groups which are smoker and non smoker. The sample distribution for the smoking 
habits based on table 5.1 shows that majority of the sample population don’t smoke 
with 69% meawhile the smokers consist as much as 31%. 
Based on the table 5.1, the highest mean of LP-PLA2  are shown by the non-
smokers with 0,10681 ng/mL. The highest mean for the number and percentage of 
monocyte are shown by the smokers with 0,2946 103/µL and 7.43%. The significance 






















the relationship between smoking habits with monocyte is significant meanwhile the 
relationship between smoking habits with Lp-PLA2 is  not significant. 
5.1.1.1.3 Body Mass Index (BMI) 
The food diet such as malnutrition and obese at the age of 18 and above 
plays important role in causing several disease including atherosclerosis. BMI is one 
of the instrument use to measure the risk for falling into the disease. In few research 
its proven that BMI related to incidence of atherosclerosis where the BMI contributed 
in the occurance of hypertension, angina pectoris and diabetes mellitus usually in 
obese. 
Based on table 5.1, the majority of the population own normal body weight 
with 40% meanwhile the least will be the obese class III ( BMI > 40 kg/m2) with 
1%.Based on the BMI on table 5.1 it shows the highest mean of LP-PLA2  own by 
the underweight category with 0,10788 ng/mL meanwhile the highest mean for the 
number and percentage of monocyte own by obese class III with 0,4201 103/µL and 
8.90%. The significance show by body mass index (BMI) with Lp-PLA2 and monocyte 
are 0,024 and 0,036 which means the relationship between body mass index (BMI) 
with monocyte and Lp-PLA2  are significant. 
5.1.1.1.4 Blood pressure 
The abnormal blood pressure also lead to several disease especially high 
blood pressure always present in the case of atherosclerosis and be proven by some 
research. The blood pressure is categorized into two groups which are normal blood 
pressure (90/60 – 130/80 mmHg) and high blood pressure (> 130/80 mmHg). The 
table 5.1 shows the sample distribution with high blood pressure is higher as much 
as 69% meanwhile those with normal blood pressure is 31%. 
Based on the table 5.1, the highest mean of LP-PLA2  consist by the normal blood 
pressure with 0,10838 ng/mL meanwhile the highest mean for number and percentage 






















significance show by blood pressure with Lp-PLA2 and monocyte are 0,028 and 0,031 
which means the relationship between blood pressure with monocyte and Lp-PLA2  are 
significant. 
5.1.1.1.5 Fasting Blood Sugar 
Rate of  sugar in blood is one of the important factor that contributing to the 
mechanism of homeostasis and body metabolism. The rate of fasting blood sugar is 
categorized into three groups consist of low fasting blood sugar (< 70 mg/dL), normal 
fasting blood sugar (70–99 mg/dL), and high fasting blood sugar (> 99 mg/dL). The 
distribution of the fasting blood sugar shows that the majority is sample population 
with low fasting blood sugar with 52% meanwhile the percentage of sample 
population with normal fasting blood sugar will be 20 % and the percentage of 
sample population with high fasting blood sugar will be 28% 
Based on the table 5.1, the highest mean of LP-PLA2  own by the low fasting 
blood sugar with 0,10637 ng/mL meanwhile the highest mean of number and 
percentage of monocyte own by the high fasting blood sugar with 0,2827 103/µL and 
7.89%. The significance show by fasting blood sugar with Lp-PLA2 and monocyte are 
0,039 and 0,045 which means the relationship between fasting blood sugar with 
monocyte and Lp-PLA2  are significant. 
5.1.1.1.6 Lipid Profile  
Lipid profile also plays major role in the occurance of atherosclerosis. Table 
5.1 shows the lipid profile categorized into two groups which are with the condition 
of dyslipidemia marked by high Low Density Lipoprotein (LDL) or low High Density 
Lipoprotein (HDL) and the other group will be non dyslipidemia. The lipid profile 
distribution shows that  majority of the sample population have the condtion of 
dyslipidemia as much as 87% and those normal consist as much as 13%.  
Based on table 5.1, the highest mean of the LP-PLA2  own by the group of sample 






















the number and percentage of monocyte own by the group of sample population with 
dyslipidemia with 0,2711 103/µL and 7.01%. The significance show by lipid profile with 
Lp-PLA2 and monocyte are 0,072 and 0,041 which means the relationship between lipid 
profile with monocyte is significant meanwhile the relationship between lipid profile with 
Lp-PLA2 is  not significant. 
 








Percentage (%) 86 4,2 11 6,9964 1,4992 
Number (103/µL) 86 0,1681 0,4201 0,2716 0,0573 
Concentration of LP-PLA2  86 0,0831 0,1381 0,1057 0,0083 
 
             The table above shows the characteristic of the variables. The mean number 
and percentage of monocyte is 0,2716 and 6,994 with standard deviation 0,0573 and 
1,4992. The minimum number and percentage of monocyte is 0,1681 and 4,2 with 
maximum 0,4201 and 11,0. Meanwhile, the mean concentration of LP-PLA2  is 0,1057 
with standard deviation 0,0083. The minimum concentration of LP-PLA2  is 0,0831 and 
the maximum 0,1381. 
5.3 Data Analysis 
          First of all the data need to fulfil the rule of normality test before proceed with 
parametric test. The aim of this research is to find out the relationship between two 
variables. Thus correlation test was the suitable test to show the relationship. If the data 
normally distributed, then Pearson correlation test will be done. If the data not normally 
Table 5.2 Minimal,Maximum,Mean And Standard Deviation Of 






















distributed, then parametric test will replace with non-parametric test which is known 
as Spearman correlation test. The tests was done with the SPSS software version 24. 
5.3.1 Data Normality Test 
Following is the hypothesis used for the assumption of the test : 
H0 : Data normally distributed  
H1 : Data not normally distributed  
The decision taken based on probability (sig,2-tailed). 
• If the probability (sig.2-tailed) > 0,05 then H0 accept 
• If the probability (sig.2-tailed) < 0,05 then H0 reject 
 
Normality Test Between The Data Of Monocytes And LP-PLA2  
 
 Kolmogorov Smirnov Probability 
Monocyte 0.072 0.200 
LP-PLA2 0.115 0.007 
 
Based on the table above, it can be seen that normality test with monocyte and 
LP-PLA2  produces Kolmogorov Smirnov statistics, respectively 0.072 and 0.115 with 
a probability of 0.200 and 0.007. It can be seen that normality test of monocyte data 
produces a probability > alpha (5%), so that the monocyte data is declared normally 
distributed meanwhile LP-PLA2  data produces a probability < alpha (5%), so that the 
LP-PLA2  data is declared not normally distributed. 
 
5.3.2 Spearman Correlation Test 
 The categorisation is done based on guidelines for interpretation of correlation 
coefficients according to Jonathan Sarwono, 2009. 

























Result Of Spearman Correlation Analysis 
 
Based on the table above, the relationship between monocytes and LP-PLA2  
produces a probability value of 0.028. These results indicate the probability is less than 
the level of significance (p < α=5%). Thus it can be stated that there is a significant 
relationship between monocytes and LP-PLA2 . The positive correlation coefficient 
indicates that the relationship between monocyte and LP-PLA2  concentration is directly 
proportional, meaning that the higher the rate of monocyte, the higher the concentration 
of LP-PLA2 . The correlation coefficient 0.789 is categorised as very strong. This mean 
that the relationship between rate of monocyte and LP-PLA2  concentration is 







0 No correlation 
0,00 - 0,25 Weak correlation 
0,25 - 0,50 Correlate 
0,50 - 0,75 Strong correlation 
0,75 - 0,99 Very strong correlation 




Variable 1 Variable 2 
Monocyte LP-PLA2  0,789 0,028 
Table 5.5 Guidelines For Interpretation Of Correlation Coefficients 
According To Jonathan Sarwono, 2009 

























           The aim of this research is to investigate the relationship between LP-PLA2  
( Lipoprotein-Associated Phospholipase A2) and monocyte on the population with risk 
factors of atherosclerosis. The blood sample collected from the sample population from 
Kota Malang. Below are the discussions based on the results received. 
 
6.1 Concentration Of LP-PLA2  On The Population With Risk Factors Of 
Atherosclerosis 
            LP-PLA2  is secreted by the inflammation cells which is monocytes. LP-PLA2  
will bind with the oxidized low-density lipoprotein (oxLDL) and break it into lysoPC and 
OxNEFA (Steen and O’Donoghue, 2013). LP-PLA2  inducing formation of potential lipid 
mediator through hydrolysis fatty acids. It shows that increase in the concentration of 
LP-PLA2  in the blood indicating signs of plaque formation. It also shows that inhibiting 
the activity of LP-PLA2  reduce the lesion of intimal and progressive of atherosclerosis 
(Lind et al., 2012). Few research also mentioning that increase in inflammatory cells 
induce concentration of LP-PLA2  to increase on the atherosclerotic plaque (Sertic et 
al.,2010). 
           LP-PLA2  is related with the risk factors of atherosclerosis such as gender, age, 
smoking habits, body mass index(BMI), blood pressure, blood glucose level and lipid 
profile. Gender itself independently influenced the exitance of  LP-PLA2 where male 
have high tendency of high concentration of LP-PLA2  compare to female (Brilakis et 
al., 2008).The research also proves that there is significant relationship between 
gender and Lp-PLA2 . High concentration of LP-PLA2  at the age of 62 and below 
indicating increase in risk factor of coronary heart disease meanwhile this is not 






















research also proves that there is significant relationship between age and Lp-PLA2 . 
Smoking habits also influence the concentration of LP-PLA2 . It shows active smokers 
have high concentration of Lp-PLA2  (Tibuakuu et al., 2018). Despite the research 
shows not significant relationship between smoking habits and Lp-PLA2. The high body 
mass index (BMI) cause the concentration of LP-PLA2  to increase (da Silva, Timm and 
Damasceno, 2013). The research also proves that there is significant relationship 
between BMI and Lp-PLA2 . In the case of hypertension, blood pressure directly 
proportional to the concentration of LP-PLA2  where both increase together (Kim et al., 
2017). The research also proves that there is significant relationship between blood 
pressure and Lp-PLA2 . There is.a research proved that diabetic retinopathy patients 
have high concentration of LP-PLA2 . This is indicating high content of sugar in blood 
will induce to increase of LP-PLA2  concentration (Siddiqui et al., 2018). The research 
also proves that there is significant relationship between fasting blood sugar and Lp-
PLA2 . Furthermore, patient with dyslipidemia who undergoing hypolipidemic 
medication shows reduction in LDL level and LP-PLA2  concentration in the blood 
(Saougos et al., 2007). But the research shows there is no significant relationship 
between lipid profile and Lp-PLA2. 
             This research is done on the population with risk factors of atherosclerosis at 
Kota Malang. Concentration of LP-PLA2  were measured using the Enzyme-Linked 
Immunosorbent Assay (ELISA) method from the blood sample collected. Based on the 
measurement of LP-PLA2  concentration, the mean of the LP-PLA2  concentration is 
0.1057 ng/mL. Based on the data received, it shows that the mean of LP-PLA2  is high 
on the male sample with 0.1058 ng/mL, age group of 50-69 years old with 0.10702 
ng/mL, non-smokers with 0.10681 ng/mL, body mass index (BMI) with underweight 
category with 0.10788 ng/mL, on the sample population with normal blood pressure 
with 0.10838, on the sample population with low blood sugar level with 0.10637 ng/mL 






















the mean of LP-PLA2  is low on the female sample with 0.1055 ng/mL, age group of 30-
49 years old with 0.10367 ng/mL, smokers with 0.10316 ng/mL, body mass index (BMI) 
with overweight category with 0.10381 ng/mL, on the sample population with high blood 
pressure with 0.10442 ng/mL, on the sample population with high blood sugar level 
with 0.10461 ng/mL and on the sample population with dyslipidemia with 0.10541 
ng/mL. Gender, age, body mass index (BMI), blood pressure and fasting blood sugar 
shows significant relationship with Lp-PLA2. 
             Based on the previous research done on LP-PLA2  proves that increase in risks 
factors able increase in concentration of LP-PLA2  and able to be related with the result 
of LP-PLA2  concentration received. Its proven that the tendency for man is high 
compare to female to have high concentration of LP-PLA2 . The research also proves 
that increase in age also increase the concentration of LP-PLA2 . This happens 
because during aging and lifestyle of a human cause deposition of fats, calcium, and 
fibrous tissue increase at the artery. Despite there is difference in the result received 
compare with previous research related to smoking habits and concentration of LP-
PLA2  which proves cause dysfunction of endothelial and increase the concentration of 
LP-PLA2 . There is a research shows that increase in body mass index (BMI) lead to 
increase in concentration of LP-PLA2  which is different from the result received. There 
is difference in the result received compare to previous research which shows increase 
in blood pressure lead to increase in concentration of LP-PLA2 . In the other research, 
it shows that dyslipidemia condition is directly proportional to concentration of LP-PLA2  
which both increase together but does not suits the data received from this research. 
               It can be concluded that concentration of LP-PLA2  is high on the population 
with risk factors such as male, increase in age, non-smokers, underweight,normal 
blood pressure, low fasting blood sugar and non-dyslipidemia. Meanwhile 
concentration of LP-PLA2  is low on the population with risk factors such as female, 






















pressure, increase in blood glucose level and with condition of dyslipidemia. There are 
significant relationship between Lp-PLA2  with gender, age, body mass index (BMI), 
blood pressure and fasting blood sugar. 
 
6.2 Number and Percentage Of Monocyte On The Population With Risk Factors 
Of Atherosclerosis 
              Monocyte in atherosclerotic lesions produce foam cells by breaking down 
oxLDL that contain lipid droplets. The accumulation of foam cells contributes to lipid 
storage and atherosclerotic plaque growth. The atherosclerotic plaque has a decreased 
ability to migrate, leading to the resolution of inflammation and the development of 
further lesions into complex atherosclerotic plaques (Rafieian-Kopaei et al., 2014). 
              Some of the risk factors of atherosclerosis such as gender, age, smoking 
habits, body mass index (BMI), blood pressure, blood glucose level and lipid profile 
seems related with number and percentage in the body. The previous research shows 
that there is relationship between gender and number and percentage. Female has 
high number and percentage compare to male due to estrogen hormone which has 
immunoenchancing factor (Jacob Roved, 2017). Age factor also influence the number 
and percentage where the older a person get the number and percentage increase 
(Olivares, Ducimetière, & Claude, 1993). Smoking habits also increase the number and 
percentage. This happens because each time a person smokes the platelet activated 
and increase number and percentage (Schaberg et al., 1997).  There is research shows 
that body mass index (BMI) with obese category will lead to increase in number and 
percentage (Rogacev et al., 2010). High blood pressure which is above 130/80 mmHg 
is related with number and percentage. High blood pressure cause the number and 
percentage increase (Maekawa et al., 2002). There is a positive correlation between 
number and percentage and blood sugar level both increase together (Ha et al., 2002). 






















patient with dyslipidemia condition due to LDL induce increase in number and 
percentages (Korporaal and Akkerman, 2006). 
               Based on the results received, mean of number and percentage of monocyte 
in this research will 0,2716 103/µL and 6.996%. Based on the data, mean of number 
and percentage of monocyte is high in male with 0,2873 103/µL and 7.262%, age group 
of 30-49 with 0,2819 103/µL and 7.177%, smokers with 0,2946 103/µL and 7.427%, 
body mass index (BMI) category obese class III with 0,4201 103/µL and 8.9%, sample 
population with high blood pressure with 0,2833 103/µL and 7.25%, sample population 
with high blood sugar level with 0,2827 103/µL and 7.89% and on sample population 
with dyslipidemia condtion with 0,2711 103/µL and 7.011%. Meanwhile the mean of 
number and percentage of monocyte is low in female with 0,2538 103/µL and 6.697%, 
age group of 50-69 with 0,2650 103/µL and 6.896%, non-smokers with 0,2654 103/µL 
and 6.882%, normal body mass index (BMI) with 0,2694 103/µL and 6.785%, sample 
population with normal blood pressure with 0,2521 103/µL and 6.572%, sample 
population with low blood sugar level with 0,2686 103/µL and 6.758% and sample 
population with non-dyslipidemia condition with 0,2748 103/µL and 6.972%. 
                Based on previous research done on monocyte proves that increase in risks 
factors able increase in number and percentage and able to be related with the result 
of monocyte received. Despite there is difference in the result of monocyte received 
compare with previous research related to gender and number and percentage which 
proves female has high number and percentage compare to male but there is significant 
relationship between gender and monocyte. There is difference in the result received 
compare to previous research which shows increase in age group lead to increase in 
number and percentage which proves the significant relationship between age and Lp-
PLA2. There is a research shows that number and percentage increase in the smokers 
since each time of smoking induce increase in number and percentages which proves 






















mass index (BMI) is directly proportional to number and percentage cause both 
increase together which proves significant relationship between BMI and monocytes. 
The increase in blood pressure will lead to increase in number and percentage which 
proves significant relationship between blood pressure and monocytes. There is a 
research shows that increase in blood sugar level induce to increase in number and 
percentage. Furthermore, the patient with dyslipidemia condition has high number and 
percentage due to increase in the rate of LDL. Both research proves that it have 
significant relationship with Lp-PLA2. 
             It can be conclude that number and percentage increase on the population with 
risk factors of atherosclerosis such as smokers, increase in body mass index (BMI), 
high blood pressure, high blood sugar level and population with dyslipidemia condition. 
Meanwhile number and percentage decrease on the population with risk factors of 
atherosclerosis such as female, non-smoker, normal body mass index (BMI), normal 
blood pressure, low blood sugar level and non-dyslipidemia condition. There are 
significant relationship between monocyte with gender, age, smoking habits, body 
mass index(BMI), blood pressure, fasting blood sugar and lipid profile. 
 
 
6.3 Analysis Correlation Between LP-PLA2  And Monocyte On The Population 
With Risk Of Atherosclerosis 
 
              Lipoprotein-associated phospholipase A2 (LP-PLA2 ) is produced by the 
monocyte (Detopoulou et al., 2009). Based on the research done, high activity of LP-
PLA2  is one of the independent factor of inflammation and risk factor of cardiovascular 
disease and there is research proves that high concentration of LP-PLA2  cause 
increase the risk of stroke and coronary heart disease (Cai et al., 2017). Meanwhile 






















adhesion molecule (ICAM-1), vascular cell-1 adhesion molecule (VCAM-1) and 
enhancing the endothelial adhesive properties similar to pro-inflammatory effect. 
Monocyte also produce LP-PLA2  to breakdown oxLDL into lysoPC and OxNEFA. 
These particles will cause the formation of fibrous cap on the blood vessel (Badimon, 
Padró and Vilahur, 2012). 
               Monocyte secreted Lp-PLA2. LP-PLA2  will bind with the oxidized low-density 
lipoprotein (oxLDL) and break it into lysoPC and OxNEFA (Steen and O’Donoghue, 
2013). LP-PLA2  inducing formation of potential lipid mediator through hydrolysis fatty 
acids. It shows that increase in the concentration of LP-PLA2  in the blood indicating 
signs of plaque formation. It also shows that inhibiting the activity of LP-PLA2  reduce 
the lesion of intimal and progressive of atherosclerosis (Lind et al., 2012). LP-PLA2  and 
monocyte is correlated to each other through the mechanism and it shows increase in 
number and percentage will cause increase in concentration of LP-PLA2 . 
                Based on the results obtained from this research can be stated that there is 
significant relationship between monocyte and LP-PLA2 . LP-PLA2  is directly 
proportional to monocyte which means the higher the concentration of LP-PLA2  the 
higher the number and percentage and the lower the concentration of LP-PLA2  the 


































CONCLUSION AND SUGGESTION 
 
7.1 Conclusion 
Based on the research about analysis correlation between concentration of LP-PLA2  
and monocyte on the population with conditions at risk of atherosclerosis, can be 
concluded that : 
 
• There is significant relationship between monocyte and LP-PLA2 . 
LP-PLA2  is directly proportional to monocyte which means the higher 
the concentration of LP-PLA2  the higher the number and percentage 
and the lower the concentration of LP-PLA2  the lower the number 
and percentage. 
• Concentration of LP-PLA2  on the population with condition at risk of 
atherosclerosis increase on male and increase in age. Meanwhile 
concentration of LP-PLA2  on the population with condition at risk of 
atherosclerosis decrease on female, young age group, smoking habits, 
increase in body mass index (BMI), increase in blood pressure, increase in 
blood glucose level and with condition of dyslipidemia. 
• Number and percentage on the population with condition at risk of 
atherosclerosis increase on male, increase in age, smokers, increase in 
body mass index (BMI), high blood pressure, high blood sugar level and 
population with dyslipidemia condition. Meanwhile number and percentage 






















female, non-smoker, normal body mass index (BMI), normal blood 
pressure, low blood sugar level and non-dyslipidemia condition. 
 
   7.2 Suggestion 
 Further research need to be take to investigate the activity of LP-PLA2  and 
concentration of LP-PLA2  in the process of atherosclerosis because it seems like the 
concentration of LP-PLA2  and activity of LP-PLA2  plays role on the formation of LP-
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2. Veinpuncture Prosedure 
Alat dan Bahan : 






• Kapas kering 
 
• Kapas alcohol 70% 
 




• Vacutainer merah 
 




1. Memakai handscoon. 
 
2. Meminta pasien meluruskan lengannya. 
 
3. Meminta pasien untuk mengepalkan tangannya. 
 
4. Memasangkan torniquet kira-kira 10 cm diatas lipatan siku. 
 
5. Memilih bagian vena mediana cubiti atau cephalica. Lakukan perabaan 
(palpasi) untuk memastikan posisi vena. 
 
6. Bersihkan kulit pada bagian yang akan diambil dengan kapas alkohol 
70% dan biarkan kering. 
 
7. Tusuk bagian vena dengan posisi lubang jarum menghadap ke atas. Jika 
jarum telah masuk ke dalam vena, akan terlihat darah masuk kedalam 























8. Setelah volume darah dianggap cukup, minta pasien membuka kepalan 
tangannya. 
 
9. Letakan kapas di tempat suntikan lalu segera lepaskan / tarik jarum. 
Tekan kapas beberapa saat lalu plester selama ± 15 menit. 
 






































































3. Procedure ELISA Lp-PLA2 
 
Alat dan Bahan : 
 
 
Tabel 1 Elisa kit Cat.No E0052Hu 
 
 
 Komponen Jumlah 
  
 Standard Solution (96ng/ml) 0.5ml x1 
  
 Pre-coated ELISA Plate 
12 * 8 well strips 
x1 
  
 Standard Diluent 3ml x1 
  
 Streptavidin-HRP 6ml x1 
  
 Stop Solution 6ml x1 
  
 Substrate Solution A 6ml x1 
  
 Substrate Solution B 6ml x1 
  
 Wash Buffer Concentrate (30x) 20ml x1 
  
 
Biotinylated human Lp-PLA2 
Antibody 1ml x1 
  
 User Instruction 1 
  
 Plate Sealer 2 pics 
  




• Inkubator 37oC±0.5oC 
 
• Kertas serap 
 




• Distilled water 
 























Pengumpulan spesimen : 
 
              Spesimen plasma dikumpulkan menggunakan EDTA atau heparin 
sebagai antikoagulan. Setrifus sampel selama 15 menit dengan kecepatan 2000- 
3000 RPM dalam suhu 2-8oC. 
 
Prosedur Assay : 
 
1. Siapkan semua reagen, standard solution, dan sampel seperti yang 
diinstruksikan. Bawalah semua reagen ke suhu kamar sebelum 
digunakan. Uji ini dilakukan pada suhu kamar. 
 
2. Tentukan jumlah strip yang diperlukan untuk pengujian tersebut. 
Masukkan strip dalam frames untuk digunakan. Strip yang tidak 
digunakan harus disimpan pada 2-8 ° C. 
 
3. Tambahkan 50μl standar ke standard well. Catatan: Jangan 
menambahkan antibodi ke standard well karena larutan standar 
mengandung antibodi biotinylated. 
 
4. Tambahkan 40μl sampel ke sampel well dan kemudian tambahkan 
10μl antibodi anti-Lp-PLA2 ke sampel well, kemudian tambahkan 50μl 
streptavidin-HRP untuk sampel well dan standard well (Bukan blank 
control well). Campur dengan baik. Tutupi plate dengan sealer. Inkubasi 
60 menit pada 37°C. 
 
5. Lepaskan sealer plate dan cuci 5x menggunakan wash buffer. Rendam 
dengan baik dengan setidaknya 0,35 ml wash buffer selama 30 detik 
hingga 1 menit untuk setiap pencucian. 
 
6. Tambahkan substrate solution A 50μl ke setiap well dan kemudian 
tambahkan 50μl substrate solution B ke setiap well. Inkubasikan plate 
yang ditutup dengan sealer baru selama 10 menit pada 37°C dalam gelap. 
 
7. Tambahkan 50μl Stop Solution ke setiap well, warna biru akan 
berubah menjadi kuning dengan segera. 
 
8. Tentukan Optocal density (nilai OD) dari masing-masing well segera 
menggunakan plate reader, atur pada 450 nm selama 10 menit setelah 




































4. Procedure Of Hematology Analyzer For Monocyte 
 
 
Alat dan Bahan : 
 
• Rayto RT-76006 Auto Hematology Analyser 
 
• Sampel darah vena 
 




Cara Penggunaan Alat Hematology Analyzer 
 
1. Hubungkan kabel power ke stabilisator (stavo) 
 
2. Nyalakan alt (saklar on/off yang berada pada sisi kanan atas alat) 
 
3. Alat akan beroperasi sendiri, tulisan seperti “please wait” akan tampil 
di layar display. 
 
4. Secara otomatis alat akan melakukan pengoperasian otomatis 
kemudian pemeriksaan lata belakang 
 




Cara kerja Pemeriksaan sampel Darah 
 
1. Sampel darah yang akan digunakan harus dipastikan sudah homogen 
dengan menggunakan antikoagulan 
 
2. Tekan tombol Whole Blood “WB” pada layer monitor 
 
3. Tekan tombol ID dan masukkan nomor sampel yang akan digunakan, 
tekan enter 
 
4. Tekan bagian atas dari tempat sampel dan letakkan sampel ke dalam 
adaptor 
 
5. Tutup tempat sampel dengan rapat kemudian tekan “RUN” 
 
6. Hasil akan muncul pada layar secara otomatis 
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9.Demographic Analysis Of Respondent Characteristic 
A. Homogeneity Test Between Monocyte And Lp-PLA2  Based On Gender 
Test of Homogeneity of Variances 
 Levene Statistic df1 df2 Sig. 
Monocyte 2.345 1 83 .022 
Lp-PLA2 .190 1 83 .664 
 













6.921 1 6.921 2.987 .088 
Within 
Groups 
192.334 83 2.317   





.000 1 .000 3.739 .032 
Within 
Groups 
.005 83 .000   




























 Monocyte Lp-PLA2 
Mann-Whitney U 669.500 702.000 
Wilcoxon W 1489.500 1522.000 
Z -2.030 -1.743 
Asymp. Sig. (2-tailed) .042 .081 
 
a. Grouping Variable: Gender 
 
B. Homogeneity Test Between Monocyte And Lp-PLA2  Based On Age 
 
Test of Homogeneity of Variances 
 Levene Statistic df1 df2 Sig. 
Monocyte .044 2 82 .957 
Lp-PLA2 2.003 2 82 .141 
 









































1.706 2 .853 .354 .034 
Within 
Groups 
197.549 82 2.409   





.000 2 .000 1.795 .025 
Within 
Groups 
.005 82 .000   
Total .006 84    
 
 
C. Homogeneity Test Between Monocyte And Lp-PLA2  Based On Smoking 
Habits 
Test of Homogeneity of Variances 
 Levene Statistic df1 df2 Sig. 
Monocyte 1.670 1 83 .200 
Lp-PLA2 .373 1 83 .146 
 





































3.544 1 3.544 1.503 .024 
Within 
Groups 
195.711 83 2.358   





.000 1 .000 3.161 .059 
Within 
Groups 
.006 83 .000   




D. Homogeneity Test Between Monocyte And Lp-PLA2  Based On Body 
Mass Index 
 
        Test of Homogeneity of Variances 
 Levene Statistic df1 df2 Sig. 
Monocyte 1.452 4 79 .045 
Lp-PLA2 1.211 4 79 .313 
 




































19.942 5 3.988 1.757 .131 
Within 
Groups 
179.313 79 2.270   





.000 5 .000 .991 .024 
Within 
Groups 
.005 79 .000   
Total .006 84    
 
Test Statistics 
 Monocyte Lp-PLA2 
Chi-Square 29.400a 3.624b 
df 43 80 































E. Homogeneity Test Between Monocyte And Lp-PLA2  Based On Blood 
Pressure 
 
Test of Homogeneity of Variances 
 Levene Statistic df1 df2 Sig. 
Monocyte .186 1 83 .667 
Lp-PLA2 2.073 1 83 .044 
 












8.195 1 8.195 3.560 .031 
Within 
Groups 
191.060 83 2.302   





.000 1 .000 .379 .540 
Within 
Groups 
.006 83 .000   





























 Monocyte Lp-PLA2 
Mann-Whitney U 669.500 702.000 
Wilcoxon W 1489.500 1522.000 
Z -2.030 -1.743 
Asymp. Sig. (2-tailed) .082 .028 
 
a. Grouping Variable: BP 
 
 
F. Homogeneity Test Between Monocyte And Lp-PLA2  Based On Fasting 
Blood Sugar 
Test of Homogeneity of Variances 
 Levene Statistic df1 df2 Sig. 
Monocyte .123 2 82 .884 
Lp-PLA2 .867 2 82 .424 
 








































.172 2 .086 .036 .045 
Within 
Groups 
199.082 82 2.428   





.000 2 .000 .689 .039 
Within 
Groups 
.006 82 .000   




G. Homogeneity Test Between Monocyte And Lp-PLA2  Based On Lipid 
Profile 
 
Test of Homogeneity of Variances 
 Levene Statistic df1 df2 Sig. 
Monocyte 1.103 1 83 .792 
Lp-PLA2 3.612 1 83 .016 
 




































1.354 1 1.354 .570 .041 
Within 
Groups 
197.402 83 2.378   





.000 1 .000 3.067 .084 
Within 
Groups 
.006 83 .000   




 Monocyte Lp-PLA2 
Mann-Whitney U 669.500 702.000 
Wilcoxon W 1489.500 1522.000 
Z -2.030 -1.743 
Asymp. Sig. (2-tailed) .162 .072 
 
a. Grouping Variable: Lipid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
